HF
JBIO

HRT Financial’s Jade Biosciences JBIO Stock Holding History

HRT Financial’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,422
Closed -$343K – 4171
2026
Q1 		$343K Buy
+24,422
New +$354K ﹤0.01% 2776
2024
Q1 		– Sell
-270
Closed -$213K – 2304
2023
Q4 		$213K Buy
+270
New +$138K ﹤0.01% 1771
2022
Q1 		– Sell
-996
Closed -$410K – 3081
2021
Q4 		$410K Buy
+996
New +$504K ﹤0.01% 2053

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HRT Financial's JBIO Position: Q2 2026 in Review

HRT Financial sold out of Jade Biosciences (JBIO) in Q2 2026, closing a stake of 24,422 shares — an estimated $343K sold.

HRT Financial first reported a position in JBIO in Q4 2021 and held it in 3 quarters. The position peaked at $410K in Q4 2021. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • HRT Financial reported no remaining Jade Biosciences position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 24,422 Jade Biosciences shares in Q2 2026, an estimated $343K.
  • HRT Financial first reported a position in Jade Biosciences in Q4 2021 and held it in 3 quarters.
  • HRT Financial's Jade Biosciences position peaked at $410K in Q4 2021.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.